GLSHQ.US Gelesis Holdings, Inc.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 13, 2026
0.0001 0.0001
Market cap
USD 7.33K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is GLSHQ.US undervalued?

Graham number

The Graham number of Gelesis Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gelesis Holdings, Inc. fundamental analysis

No fundamental analysis for Gelesis Holdings, Inc. yet.

Gelesis Holdings, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gelesis Holdings, Inc.

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver diseas…

Full company profile